Erin Newburn, MS, PhD Associate Director, Field Applications Scientist The Battle Continues: Facing the obstacle of tumor resistance to immunotherapy treatment The immune system and cancer cells have interactions that are continuously evolving from the initial establishment of cancer to the development of metastatic disease. As research has shown, the [...]
Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Five unanswered questions regarding personalized neoantigen cancer vaccines From data presented at both AACR and ASCO in the past months, amazing progress continues to be made in the development of neoantigen vaccines. As we marvel at the growth and big steps [...]
Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Comparing and contrasting CTLA-4 and PD-L1/PD-1: A tale of two immune checkpoint inhibitors Tumor cells, which would typically be recognized by T cells as foreign, have established ways to evade the immune system. This forms the central strategy in targeting immune [...]
Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Understanding the role of Human Leukocyte Antigen in Cancer Immunotherapy The Flagpole MHC (major histocompatibility complex), also known as HLA (human leukocyte antigen) is the entire set of genes that code for proteins involved in antigen presentation. Very simply, you could [...]
As immunotherapy translational research studies using RNA data provide new clues to patient response, identifying the upfront technical factors affecting success is vital.
Recent advancements in RNASeq technology have revolutionized the search for the genes and gene expression signatures that determine immunotherapy response by providing a high throughput method of comprehensively examining changes in these functional elements.
The premise of the right drug for the right patient at the right time is critical for indications from cardiovascular and infectious disease to the latest immuno-oncology strategies. It’s imperative to comprehend which patient will derive benefit from ...
Tumor mutational burden (TMB) has now been established as a positive predictive biomarker of response to immune checkpoint inhibitors with more studies demonstrating correlations between the overall mutational landscape and clinical benefit ...
Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advances in attaining significant and sustained response rates.
Unlike targeted therapies, there tends to be general agreement that it is unlikely that a single predictive biomarker in tumor biopsies will be found for determining response to immunotherapies.